Cancer-Associated Atherothrombosis: The Challenge
Int J Angiol DOI: 10.1055/s-0041-1729920The association between venous thrombosis and malignancy, having typical features of a paraneoplastic syndrome, has been established for a century. Currently, it is recognized that arterial thromboembolism (ATE) may also behave as a paraneoplastic syndrome. Recent matched cohort studies, systematic reviews, and observational studies concur in showing an increased incidence of acute coronary events, ischemic stroke, accelerated peripheral arterial disease, and in-stent thrombosis during the 6-month period before cancer diagnosis, peaking for 30 days immediately before cancer diagnosis. Cancer patients with ATE are at higher risk of in-hospital and long-term mortality as compared with noncancer patients. In the present review, we focus on the epidemiology, clinical variants and presentation, morbidity, mortality, primary and secondary prevention, and treatment of cancer-associated ATE. The awareness that cancer can be a risk factor for ATE and that cancer therapy can initiate cardiovascular complications make it mandatory to identify high-risk patients, modify preexistent cardiovascular risk factors, and adopt effective antithrombotic prophylaxis. For ATE prophylaxis, modifiable patient-related risk factors and oncology treatment–related factors are levers for intervention. Statins and platelet antiaggregants have been studied, but their efficacy for prevention of cancer-associated ATE remains to be demonstrated. Results of revasculariz...
Source: International Journal of Angiology - Category: Cardiology Authors: Naschitz, Jochanan E. Tags: Review Article Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Cholesterol | Epidemiology | Heart | Hospitals | Ischemic Stroke | Palliative | Paraneoplastic Syndrome | Radiology | Statin Therapy | Stroke | Study | Thrombosis